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Abstract
Background: Kaposi’s sarcoma (KS) in HIV negative patients is rare and has to be distinguished from AIDS associated KS.
Two groups are at risk to develop non-AIDS related KS: elderly men mainly of Mediterranean origin and persons with
iatrogenic immunosuppression.
Patients and Methods: In order to define risk-groups and major clinical features we retrospectively evaluated clinical data of
all patients with non-AIDS associated KS presenting to the Department of Dermatology, University Hospital Tuebingen
between 1987 and 2009. Data were extracted from the tumor registry of the Comprehensive Cancer Center Tuebingen and
from patient records.
Results: 20 patients with non-AIDS KS have been identified. The average age at KS onset was 66.6 years; the male-to-female-
ratio was 3:1. Most of the patients were immigrants from Mediterranean or Eastern European countries (60%). 15 cases of
classic KS versus 5 cases of iatrogenic KS were observed. In 95% of the cases, KS was limited to the skin, without mucosal,
lymph node or visceral manifestation. KS lesions were in all cases multiple and mostly bilateral, the most common
localization was the skin of the lower extremities. Tumor control was achieved in nearly all cases by the use of local or
systemic therapy. No patient died from KS.
Conclusions: Unlike KS in AIDS patients, non-AIDS associated KS is a rather localized process which rarely involves lymph
nodes or organs. It is mostly seen in elderly males from Mediterranean or Eastern European countries and in most cases
responsive on local or systemic therapeutic strategies.
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Introduction
Kaposi’s sarcoma (KS) was first described in 1872 by the
Hungarian dermatologist Moritz Kaposi [1]. It is a rare neoplasm
of lymphatic endothelial cells frequently evident as multiple
vascular cutaneous and mucosal nodules. Lymph node and
visceral manifestation is seen in cases of strong immunosuppres-
sion or aggressive disease.
Four groups are at risk to develop KS: elderly males of
Mediterranean and Eastern European lineage; children and adults
from central Africa; persons who are iatrogenically immunocom-
romised; and homosexual men infected with human immunode-
ficiency virus (HIV) [2]. Major differences in clinical presentation
and in prognosis among those groups have lead to the following
classifications: classical KS, endemic or so called African KS,
iatrogenic KS and AIDS-KS.
Chang et al. discovered human herpes virus 8, (HHV-8), also
known as Kaposi’s sarcoma associated herpes virus, which is
strongly implicated in the pathogenesis of all types of KS [3]. The
herpes virus is considered necessary but not sufficient for the
development of KS, which is a multistep process including not
only HHV-8 infection, but also genetic and angiogenic factors, as
well as the production of several inflammatory cytokines [4].
To date it remains unclear whether KS itself is a true
malignancy or rather just a reactive proliferation [5].
This study focuses on non-AIDS related KS of the skin i.e.
cutaneous manifestations of KS in HIV-negative patients present-
ed to the Department of Dermatology, University of Tuebingen
Medical Center between 1987 and 2009.
Materials and Methods
This is a retrospective descriptive study of a series of 20 patients
admitted consecutively for KS, from 1987 to 2009 in the
Department of Dermatology, University of Tuebingen Medical
Center. Informed consent was not obtained for all patients as the
entire data was analyzed anonymously. This applies according to
the German Medical Association’s professional code of conduct
and has been approved by the Ethics Committee, University of
Tuebingen (Figure S1).
In order to define risk-groups and major clinical features we
retrospectively identified cases registered by the tumor registry of
the Comprehensive Cancer Center Tuebingen and evaluated
clinical data documented in the hospital records.
All cases presented histopathologically approved KS lesions of
the skin and negative HIV-1/2 screening by macro enzyme
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by immunohistochemical tests such as HHV-8 staining, or
immunostaining with antibodies against endothelial markers D2-
40, CD31 and CD34. Most patients underwent tumor staging by
lymph node and abdominal ultrasound as well as chest x-ray.
Demographic features such as origin, age at onset, gender of the
patient, as well as clinical features such as clinical subtype of KS and
localization of lesions were evaluated. Furthermore treatment
modalities, results and tumor recurrence in the time of observation
were recorded. Treatment outcome was classified according to the
Response Evaluation Criteria in Solid Tumors (RECIST Guide-
lines) [6]. One patient had a stable disease course and therefore did
notneed treatment and onepatientrefusedtherapy. Mediantime of
follow-up for all patients were four years (SEM=7.86 months). In 7
cases time of observation was determined by intercurrent death.
Causes of death were other than KS in all cases.
Statistical package of social sciences 16.0 software (SPSS Inc.,
Chicago, IL, U.S.A.) was used to calculate means and standard
deviations.
Results
20 cases of non-AIDS KS were identified in this study. Mean
age at diagnosis of the group was 66.6 year-old (SD=15.36). The
youngest patient was 36-year-old and iatrogenically immunosup-
pressed; the oldest developed his classic KS by the age of 90.
Mean age at onset of patients with classic KS was 69.6 years
(SD=12.09).
A male predominance in KS – 75% male patients (n=15) versus
25% female patients (n=5) was shown with a male/female ratio of
3:1.
60% (n=12) of the patients observed in Tuebingen were
immigrants from Mediterranean and Eastern European countries
(all first generation) versus eight German patients.
Regarding the clinical Subtype 15 cases of classic KS and five
cases of iatrogenic KS were identified.
Iatrogenic immunosuppression was in one case used for a liver
transplant-patient and four patients were under immunosuppres-
sive therapy due to autoimmune diseases i.e. Behc ¸et’s disease,
myasthenia gravis, chronic membranous glomerulonephritis and
systemic sarcoidosis. Immunosuppressive medication included
systemic corticosteroids in all five cases in addition to azathioprine
in one case and ciclosporin A in two cases.
One patient was categorized as classic KS even though
presenting a primary nodal peripheral T-cell lymphoma causing
immunosuppression. However, immunosuppression was in this
case not iatrogenically induced.
In 95% (n=19) of the cases, KS was limited to the skin, without
mucosal, lymph node or visceral manifestation.
One patient presented mucosal lesions of the oral and genital
region as well as inguinal lymph node invasion.
KS lesions were multiple in all patients (n=20), no patient
presented just one singular lesion. 70% of the patients (n=14) were
affected on both hemispheres of the body and 30% (n=6)
presented unilateral lesions.
The most frequent manifestation was the skin of the lower leg
(n=8), six patients were affected on their feet and five patients on
all four extremities. All in all 95% of the patients were affected on
the skin of the lower extremities.
Figure 1 and 2 present a patch stage classic KS characterized by
several brownish irregularly-shaped maculae as well as the
existence of a few partly indurated plaques.
All stages of KS lesions were observed within the group: The
initial patch stage exhibits an irregular proliferation of jagged
vascular channels in the dermis below an integral epidermis. The
so-called promontory sign is sometimes found in patch stage
lesions and denotes vascular spaces surrounding pre-existing blood
vessels (Figure 3). Perivascular lymphoplasmocytic cells as well as
extravasated erythrocytes and hemosiderin deposits are charac-
teristic for patch stage.
As KS progresses to the plaque stage bizarre vessels with an
atypical endothelial lining dissect the collagen tissue (Figure 4). In
the nodular stage spindled endothelial cells predominate forming
slit-like vascular spaces containing erythrocytes and hyaline
globules. Figure 5 and 6 demonstrate a well-circumscript
spindle-cell tumor with poorly defined slit-like vascular spaces.
Figure 7 shows D2-40 immune staining of lymphatic endothelial
cells revealing arborizing vascular structures and lymphocytic cell
infiltration. Figure 8 displays HHV-8 stained atypical endothelial
cells.
Treatment modalities included local therapy such as surgery
and radiotherapy as well as systemic immune therapy with
interferon-a-2a. Interferon-a-2a was applied by subcutaneous
injection using 3 million international units three times weekly.
One patient developed neutralizing antibodies and therefore his
therapy was switched to Interferon alphacon (consensus interferon
9 mg daily, then every second day). The duration of administration
Figure 1. Brownish macules and plaques on the foot of a
patient with classic KS.
doi:10.1371/journal.pone.0018397.g001
Figure 2. Patch stage classic KS: Red to brownish irregularly-
shaped macules and plaques.
doi:10.1371/journal.pone.0018397.g002
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post-transplant KS immunosuppressive medication was switched
from ciclosporin A to sirolimus resulting in a partial response. One
patient had a stable disease course and therefore did not need
treatment and one patient refused therapy.
Treatment outcome was evaluated according to the Response
Evaluation CriteriainSolid Tumors (RECIST-Guidelines).The term
‘‘complete response’’ means clearance of KS lesions on later visits
whencomparedwiththefirstlesionsonadmission.‘‘Partialresponse’’
equals at least 30 percent decrease in the sum of the longest diameter
of target lesions whereas ‘‘stable disease’’ involves less than 30 percent
decrease. The terms complete and partial response as well as stable
disease implicate the absence of new lesions or of progressive lesions.
This was achieved in all cases. No patient presented a progressive
disease course initially nor died of KS. Four patients developed
multiple local recurrences. Two of them had primarily received a
local therapy and one interferon-a-2a.
Clinical features and treatment outcome of non-AIDS KS are
presented in Table 1.
Discussion
Non-AIDS KS is considered a rare disease, but incidence varies
according to individual factors such as origin, sex, age and
immune status of the patient.
Between 1987 and 2009, only 20 cases of non-AIDS related KS
were observed at the Department of Dermatology in Tuebingen,
Germany. This is in line with the low incidence of cases appearing
in North-Western Europe.
No data regarding the incidence of KS in Germany currently
exists. Iscovich et al. analyzed reports of classic KS from different
cancer registries throughout the world between 1988 and 1992.
Low incidence rates were found in Denmark (0.18 per million men
aged over 65 per year), intermediate rates in France, and especially
high rates in Sardinia and Sicily (13.2 per million men aged over
65 per year) [7].
It is worth mentioning that the majority of the non-AIDS KS in
Tuebingen (12 out of 20) have been found in first generation
immigrants from Mediterranean countries with presumably higher
incidence rates e.g. in Turkey and Italy (1 per 100,000 men per
Figure 3. Patch stage KS with promontory sign. Dilated irregular
vascular channels surround a pre-existing vessel.
doi:10.1371/journal.pone.0018397.g003
Figure 4. Plaque stage KS with bizarre vessels dissecting the
upper dermis. There is erythrocyte extravasation and hemosiderin
pigmentation.
doi:10.1371/journal.pone.0018397.g004
Figure 5. Tumor stage KS: Well-circumscript spindle-cell tumor.
Erythrocytes lie within poorly defined slit-like vascular spaces.
doi:10.1371/journal.pone.0018397.g005
Figure 6. Tumor stage KS: Close up view.
doi:10.1371/journal.pone.0018397.g006
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two largest ethnic minorities in Germany.
Mean age at onset of our 20 patients was 66.6 years. Focusing
exclusively on classic KS an average age of 69.6 years was found,
which is comparable to more comprehensive investigations like the
Italian 870-cases study conducted by Dal Maso et al. showing a
mean age of 72 years [8].
Gender presents another factor which strongly influences KS
manifestation. Former male-to-female ratios from 10:1 to 15:1 had
been reported in classic KS [9]. More recent studies showed
gender ratios ranging from 1:1 in England up to 4:1 in Italy
[10,11]. Iscovich and colleagues ascertained a lower gender
difference in populations with lower incidence rates [7]. The
Tuebingen case group showed a significant male predominance
with a male-to-female ratio of 3:1.
Just as other investigations classic KS was the most frequent
subtype we found. Iatrogenic KS was with 25% a considerately
highly represented subtype. This may be an effect of mismatch in
classification. Other studies call this subtype post transplant-KS
and patients with KS under immunosuppressive therapy for
autoimmune disorders may not be listed in this group. However
the increased risk of KS in iatrogenically immunosuppressed
patients is well documented [12–14].
One of our patients presented with a nodal peripheral T-cell
lymphoma, a hematological malignancy that possibly implicates
immunosuppression. Over fourfold significant increase of Kaposi’s
sarcoma in patients with lymphohematopoietic malignancies have
been reported in the literature [15]. Presumably immunodeficien-
cy of any kind; iatrogenic, malignant or HIV-induced is a
considerable factor in the development of KS.
Clinically, non-AIDS KS mostly presents itself as multiple
bilateral cutaneous lesions of the lower limb [7]. We found the
lesions to be multiple in 100% of the cases, they were mostly
bilateral (70%) and the lower extremity was clearly the most
affected localization (95%). Only one patient with extracutaneous
lesions was identified. This is in line with the results of Hong and
Lee who compared characteristics of KS in HIV positive and
negative subjects [16].
KS can be seen as a systemic disease with mutilocular
occurrence of vascular tumors. Thus the therapeutic administra-
tion of KS differs essentially from the management of most other
neoplastic diseases. In comparison with other tumors KS therapy
comprises growth control rather than elimination without
presenting a palliative situation. A standard therapeutic guideline
does not exist as the therapeutic options have to be chosen
depending on subtype and stage of the disease as well as on the
immune status of the patient [17].
Treatment modalities comprise local therapy for example
surgery, radiotherapy and local chemotherapy such as injections
of vinca alkaloids or local immune therapy by interferon,9 cis
retinoid acid or imiquimod [18–23]. Patients with widespread
disease may need systemic chemotherapeutic or immunologic
medication. Positive results have been found for pegylated
liposomal doxorubicin, danaurubicin, paclitaxel and interferon a
[24,25]. In patients with iatrogenic KS, immunosuppressive
medication may be reduced or modified with the considerate
possibility of grafts being rejected with insufficient immunosup-
pression [26].
Between 1987 and 2009 single KS lesions have been surgically
removed and irradiated. The immune stimulating, antiviral and
anti-proliferative properties of interferon-a-2a have been used for
both systemic and intralesional therapy. In one patient with post-
transplant KS immunosuppressive medication was switched from
ciclosporin to the m-TOR inhibitor sirolimus. Sirolimus has
immunosuppressive, anti-angiogenic and anti-neoplastic potential
[27]. Current studies confirm it’s positive effects on iatrogenic KS
[28].
We achieved complete responses in half of the patients. The rest
presented partial remissions or stable disease courses. No patient
died of KS. Due to the small number of cases we were not able to
demonstrate differences between treatments, neither were we able
to provide outcome diagnosis between different subtypes. Four
patients developed multiple local recurrences. Three of them had
primarily received a surgical therapy and one had primarily been
treated with interferon-a-2a.
In summary this study analyzed the clinical manifestation,
treatment and outcome of all patients with non-AIDS associated
KS patients presenting to the Department of Dermatology,
University Hospital Tuebingen, between 1987 and 2009. In
addition to HHV-8 infection, individual factors like origin, age, sex
and immune status of the patient seem to have an impact on the
development of KS. In contrast to AIDS-associated KS, KS in
HIV negative patients appears less aggressive, mostly limited to the
skin and well-responsive on local or systemic therapeutic strategies.
Figure 7. D2-40 staining of arborizing vascular structures;
irregular lymphatic vessels.
doi:10.1371/journal.pone.0018397.g007
Figure 8. HHV-8 staining of atypical endothelial cells.
doi:10.1371/journal.pone.0018397.g008
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Table 1. Clinical features and treatment outcome.





P1 44 Italy immune lower legs sirolimus PR -
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